Quiflapon (sodium)

Quiflapon sodium (MK-591 sodium) is a selective and specific 5-Lipoxygenase-activating protein (FLAP) inhibitor. Quiflapon sodium is an orally active Leukotriene biosynthesis inhibitor. Induces apoptosis.

Product Specifications

CAS Number

[147030-01-1]

Product Name Alternative

MK-591 (sodium)

UNSPSC

12352005

Target

Apoptosis; FLAP

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/MK591.html

Concentration

10mM

Purity

99.89

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic)

Smiles

ClC(C=C1)=CC=C1CN2C(CC(C)(C(O[Na])=O)C)=C(SC(C)(C)C)C3=C2C=CC(OCC4=NC5=CC=CC=C5C=C4)=C3

Molecular Formula

C34H34ClN2NaO3S

Molecular Weight

609.15

References & Citations

[1]Mendis C, et al. Effect of 5-lipoxygenase inhibitor MK591 on early molecular and signaling events induced by staphylococcal enterotoxin B in human peripheral blood mononuclear cells. FEBS J. 2008 Jun;275 (12) :3088-98.|[2]Sarveswaran S, et al. MK591, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells: synergistic action with LY294002, an inhibitor of phosphatidylinositol 3'-kinase. Cancer Lett. 2010 May 28;291 (2) :167-76.|[3]Park MS, et al. 5-Lipoxygenase-activating protein (FLAP) inhibitor MK-0591 prevents aberrant alveolarization in newborn mice exposed to 85% oxygen in a dose- and time-dependent manner. Lung. 2011 Feb;189 (1) :43-50.|[4]Chu J, et al. Involvement of 5-lipoxygenase activating protein in the amyloidotic phenotype of an Alzheimer's disease mouse model. J Neuroinflammation. 2012 Jun 14;9:127.